Industry News
18 Nov 2026

J&J Bolsters Retinal Pipeline with US$2.2B Acquisition of Ollin Biosciences

J&J Bolsters Retinal Pipeline with US$2.2B Acquisition of Ollin BiosciencesPhase 3 bispecific antibody OLN324 targets both VEGF and Ang2, promising extended dosing intervals for wet AMD and diabetic macular oedema.

Johnson & Johnson has announced a definitive agreement to acquire Ollin Biosciences, a clinical-stage biopharmaceutical company, in a US$2.2 billion (approx. AU$3.4 billion) upfront deal that significantly expands its footprint in the ophthalmology space.

The acquisition secures OLN324, a Phase 3 investigational bispecific antibody designed to treat retinal vascular diseases, including wet age-related macular degeneration (AMD) and diabetic macular oedema (DME). These two conditions represent a substantial daily case load for ophthalmologists and optometrists. 

A Dual-Pathway Approach

OLN324 is engineered to target two key drivers of retinal disease: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). While current standard-of-care treatments predominantly focus on VEGF inhibition, OLN324 features high Ang2 potency and utilises a small protein format (a minibody). 

According to the company, this unique structure could enable superior control of retinal fluid and offer more sustained disease management. For eyecare providers, the primary clinical advantage lies in the potential to extend the intervals between intravitreal injections, thereby reducing the treatment burden on patients and easing the scheduling pressures on busy specialist clinics.

"OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control," said Kip Connor, Vice President and Ophthalmology Disease Area Stronghold Leader at Johnson & Johnson. "The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients."

"Over the last three years, we’ve been on a mission to develop new therapies that improve the outcomes of patients with vision-threatening diseases. We’ve built a relentlessly execution-focused team and have rapidly advanced OLN324, generating compelling proof-of-concept data showing the potential for more effective improvements in retinal anatomy," said Jason S. Ehrlich, MD, PhD, Ollin’s chief executive officer and co-founder. "I am especially grateful to my colleagues and co-founders at Ollin for their efforts that led to today's announcement, and for the support of our investors. We're encouraged by what the future could hold and, subject to the completion of the transaction, the opportunity to build on our progress to date and further advance the development of OLN324 together."

Complex Financial Structuring

The US$2.2 billion upfront payment to Ollin Biosciences may be supplemented by up to US$1.125 billion in future regulatory and commercial milestone payments. 

In a notable financing move, J&J has also entered a separate development funding agreement with Blackstone Life Sciences. Contingent on the successful close of the acquisition, Blackstone will inject US$750 million over multiple years to fully fund the Phase 3 clinical advancement of OLN324. In return, Blackstone will be eligible for specific regulatory and sales milestones, alongside single-digit royalties. 

Looking Ahead

The transaction is expected to close before the end of 2026, subject to standard regulatory approvals and closing conditions. 

For the local eyecare sector, the move underscores a broader industry shift toward bispecific antibodies and dual-pathway inhibition in retinal care. With Australia's ageing population and rising rates of diabetes driving the prevalence of AMD and DME, the introduction of longer-lasting, highly potent biologics could fundamentally alter clinical management guidelines in the coming years. J&J's acquisition signals a strong commitment to accelerating these next-generation therapies toward commercial availability.